AKT1 and lung cancer: Moreover, the combination study between cisplatin and HF qualitatively evaluated in lung cancer cell lines showed increased sensitivity to cisplatin with HF exposure, and the combination of cisplatin with both Akt inhibitor and ERK inhibitor also simulated this phenomenon.